Asthma is a heterogeneous disease characterized by chronic airway inflammation which has been further elucidated over the last 30 years. This has led to a revolution of pharmacologic targets and the recognition of several biomarkers that have allowed for a more personalized approach to asthma. Up to 20% of asthmatics are considered to be refractory despite adequate maintenance inhaled therapy with frequent exacerbations and poor symptom control Vianello et al. (2019). Newly developed therapies targeting cytokines in the asthma inflammatory pathways have led to reduced exacerbations and improved symptom control and lung function in a subgroup of severe asthmatics. Further upstream targets may provide similar improvement for a broader spectrum of asthmatics.

中文翻译：

---

哮喘治疗的新进展。

哮喘是一种以慢性气道炎症为特征的异质性疾病，在过去的 30 年中已得到进一步阐明。这导致了药理学靶点的革命和对几种生物标志物的认可，这些生物标志物允许更个性化的哮喘治疗方法。高达 20% 的哮喘患者被认为是难治性的，尽管进行了充分的吸入性维持治疗，伴有频繁的恶化和症状控制不佳 Vianello 等人。(2019)。新开发的针对哮喘炎症通路中细胞因子的疗法已导致重度哮喘患者亚组的恶化减少并改善症状控制和肺功能。进一步的上游目标可能为更广泛的哮喘患者提供类似的改善。